METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE
The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
1 . A method for treating obstructive coronary artery disease comprising:
(a) administering to a mammalian subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof; and
(b) performing a coronary artery bypass graft procedure (CABG) on the subject.
2 . The method of claim 1 , wherein the subject is administered the peptide prior to the CABG procedure.
3 . The method of claim 1 , wherein the subject is administered the peptide after the CABG procedure.
4 . The method of claim 1 , wherein the subject is administered the peptide during and after the CABG procedure.
5 . The method of claim 1 , wherein the subject is administered the peptide continuously before, during, and after the CABG procedure.
6 . The method of claim 5 , wherein the subject is administered the peptide for at least 3 hours after the CABG procedure.
7 . The method of claim 5 , wherein the subject is administered the peptide for at least 5 hours after the CABG procedure.
8 . The method of claim 5 , wherein the subject is administered the peptide for at least 8 hours after the CABG procedure.
9 . The method of claim 5 , wherein the subject is administered the peptide for at least 12 hours after the CABG procedure.
10 . The method of claim 5 , wherein the subject is administered the peptide for at least 24 hours after the CABG procedure.
11 . The method of claim 5 , wherein the subject is administered the peptide starting at least 8 hours before the CABG procedure.
12 . The method of claim 5 , wherein the subject is administered the peptide starting at least 5 hours before the CABG procedure.
13 . The method of claim 5 , wherein the subject is administered the peptide starting at least 2 hours before the CABG procedure.
14 . The method of claim 5 , wherein the subject is administered the peptide starting at least 1 hour before the CABG procedure.
15 . The method of claim 5 , wherein the subject is administered the peptide starting at least 30 minutes before the CABG procedure.
16 . The method of claim 1 , wherein the peptide is administered by a systemic intravenous infusion commencing about 30 minutes before the induction of anesthesia.
17 . The method of claim 1 , wherein the peptide is administered in conjunction with a cardioplegia solution.
18 . The method of claim 1 , wherein the peptide is administered as part of the priming solution in a heart lung machine during cardiopulmonary bypass.
19 . The method of claim 1 , wherein the levels of one or more of N-terminal pro-brain natriuretic peptide (NT-proBNP), glucose, and estimated glomerular filtration rate (eGFR) are reduced in a subject administered the peptide relative to a comparable subject undergoing a CABG procedure, but not administered the peptide.
20 . A method for preventing renal or cerebral complications during a coronary artery bypass graft procedure (CABG) procedure, the method comprising:
(a) administering to a mammalian subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof; and
(b) performing a coronary artery bypass graft procedure (CABG) on the subject.